GPCR compared with ARWR: revenue, margins and what each company keeps, and the suppliers and customers both name

GPCRStructure Therapeutics Inc.

Mkt capRevenueRevenue

ARWRArrowhead Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

GPCRStructure Therapeutics Inc.

ARWRArrowhead Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only GPCR 0

None

Shared 0

No disclosed counterparties: GPCR.

Only ARWR 4

AMGNAmgencustomer

SRPTSarepta Therapeuticscustomer

NVSNovartis Pharmacustomer

—Takeda Pharmaceuticalunlistedcustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

GPCRStructure Therapeutics Inc.

20.76▼−5.10%

Mkt cap$4.8BRevenue—Revenue—

ARWRArrowhead Pharmaceuticals, Inc.

60.03▲+0.21%

Regular sessionNov 2 '26

Mkt cap$8.5BRevenue$75MQ3 FY26Revenue$829MFY25

Compare

Regular sessionNov 2 '26

GPCRStructure Therapeutics Inc.

ARWRArrowhead Pharmaceuticals, Inc.

20.76▼−5.10%

Price

60.03▲+0.21%

$4.8B

Mkt cap

$8.5B

—

Revenue

$75MQ3 FY26

—

Revenue

$829MFY25

GPCR20.76▼−5.10%vsARWR60.03▲+0.21%Regular sessionNov 2 '26